stockchase picture

Compiling comments that experts make about stocks while on public TV.

There are 2 registered members and 142 guests viewing this site

Company Index

List by Company Name

All | 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

List by Symbol

All | 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Abbott Labs

Stock Symbol: ABT-N

Last Price Recorded: 37.7200 on 2013-05-23 01:14:01

Globe 200 day average
Google Discussions (view only)
yahoo discussion
Date Signal Expert Opinion Price
2012-10-24 COMMENT Gordon Reid

Going to spin off the pharma portion and their nutritional and diagnostic group. When they first announced the spinoff, the stock was in the mid-$50’s so it has done fairly well but it has come down on earnings. You have to be careful with spinoffs as they are technically designed for US holders and US taxation. Sold his holdings about 6 months ago.

 Price:
$65.560
Subject:
US EQUITIES
Bias:
BULLISH
Owned:
No
2012-10-11 TOP PICK David Burrows

2.9% dividend. Going down the path into splitting into two businesses. The pharma business has a higher than industry growth rate. Best performing sector in the market at present. The patent cliff is here and priced into the stock price.


 Price:
$69.420
Subject:
NORTH AMERICAN - LARGE
Bias:
SELECTIVE
Owned:
Yes
2012-09-25 HOLD Jeff Black

Great quality company. They are splitting their medical devices and pharmaceuticals but if you own, stay the course. Likes the space. Have executed well.

 Price:
$69.570
Subject:
NORTH AMERICAN - LARGE & ETFs
Bias:
BEARISH
Owned:
Yes
2012-09-14 HOLD David Driscoll

They are going to split off their medical device and their pharmaceutical division. This is in kind of a Hold mode right now until the split comes through. This is a company that has raised its dividend historically. Free cash flow is a very good. When the split comes, hang on to both shares. You’ll probably see your average cost base cut in half.

 Price:
$68.270
Subject:
GLOBAL
Bias:
DEFENSIVE
Owned:
No
2012-09-04 TOP PICK Hap (Robert) Sneddon FCSI

Has got a really good pipeline and well owned by institutions.  Great triple A balance sheet and a good yield.  Screens well against S&P stocks.  Slight sideways action.  Company will be splitting into two components in the future.  This will unlock value.

 Price:
$65.460
Subject:
TECHNICAL ANALYSIS
Bias:
CAUTIOUS
Owned:
Yes
2012-08-07 BUY David Baskin

(Market Call Minute.) Broadly diversified healthcare company with proprietary drugs, non-prescription drugs and medical devices. Growing nicely

 Price:
$66.030
Subject:
NORTH AMERICAN - LARGE
Bias:
OPTIMISTIC
Owned:
Yes
2012-07-09 COMMENT Christine Poole Will be splitting the company into 2 parts, pharma side and medical devices. Purchased a generic company out of India last year and India will be providing health care to the general population but will only pay for generic drugs . Currently within a couple of dollars of her target price so she might shave some of her holdings.
Price:
$65.610
Subject:
NORTH AMERICAN - LARGE
Bias:
CAUTIOUS
Owned:
Yes
2012-05-17 TOP PICK David Burrows This has been one of the strong companies in the ethical drug companies. Have grown their dividend 10% at year over the last 10 years. Has been a very steady company. Traded sideways for 12 years in a price range and recently in the last year, broke out. They are going to split this company into a medical products/devices company and a pure pharma business. The pharma business will have a high yield attached and the other part has opportunities for efficiencies and growth.
 Price:
$62.230
Subject:
NORTH AMERICAN - LARGE
Bias:
CAUTIOUS
Owned:
Yes
2012-05-09 WAIT Gordon Reid (Market Call Minute.) Splitting in two. Their pharma business is going to be priced more cheaply but be careful because their major drug is 47% of this. To concentrated. He would look at the other piece when they split.
 Price:
$61.230
Subject:
US EQUITIES
Bias:
BULLISH on US MARKET
Owned:
No
2012-04-19 BUY Stan Wong This is a more of a growth company in the healthcare space. You are looking at higher single-digit growth and you are getting it for around 11-12 times PE. Nice dividend at around 3.4%.
 Price:
$59.510
Subject:
NORTH AMERICAN - LARGE & ETFs
Bias:
CAUTIOUS
Owned:
No
2012-03-15 TOP PICK Gavin Graham Splitting itself into two businesses – Pharma and Infant nutrition. Couple of interesting acquisitions in the last year and a half. 3.6% yield.
Price:
$59.110
Subject:
NORTH AMERICAN - LARGE & GLOBAL EQUITIES
Bias:
DEFENSIVE
Owned:
Yes
2012-02-09 BUY Brian Acker, CA Has Merck and Pfizer. There was no time when you could buy it this cheaply except for the August correction.
Price:
$55.260
Subject:
NORTH AMERICAN - LARGE
Bias:
BULLISH
Owned:
No
2011-11-29 BUY on WEAKNESS Norman Levine Fundamentally he likes it. Operationally it is performing as it should. They are tied into the European economy and people are worried about the EU economies, although their sales are holding up. Getting hurt by tax-loss selling.
 Price:
$53.050
Subject:
NORTH AMERICAN - LARGE
Bias:
DEFENSIVE
Owned:
Unknown
2011-10-24 COMMENT Norman Levine Likes health care companies generally because they’re defensive. Splitting their drug company from the rest of the company. Likes this as you get pure plays.
 Price:
$53.450
Subject:
NORTH AMERICAN - LARGE
Bias:
CAUTIOUS
Owned:
No
2011-10-24 SELL ON STRENGTH Gordon Reid Half of business in Pharma space and rest is in nutritional area.
 Price:
$53.450
Subject:
US EQUITIES
Bias:
DEFENSIVE
Owned:
No
Showing 16 to 30 of 61 entries

No Comments.

You must be logged in to comment.